The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1059
August 13, 1999
View Complete Issue         Table of Contents 2019 
Rosiglitazone for Type 2 Diabetes Mellitus
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Rosiglitazone for Type 2 Diabetes Mellitus
August 13, 1999 (Issue: 1059)
Rosiglitazone, the second thiazolidinedione derivative to be marketed in the USA for treatment of type 2 diabetes, has been approved by the FDA for use either alone or combined with meformin.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Rosiglitazone for Type 2 Diabetes Mellitus
Article code: 1059a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.